Related Experiment Video
Updated: Apr 12, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Association between MTHFR 677C/T polymorphism and psoriasis risk: a meta-analysis
1Department of Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
Abstract:
Previous studies investigating the association between methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphisms and psoriasis risk have reported inconsistent results. The present meta-analysis aimed to comprehensively evaluate the association between MTHFR 677C/T polymorphism and psoriasis risk. The studies regarding the association between MTHFR 677C/T polymorphism and psoriasis risk were retrieved from the PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure, and Chinese Biomedical databases. Data were extracted and statistical analysis was performed with the program STATA 12.0. A total of seven studies involving 1290 psoriasis cases and 1068 healthy controls were retrieved. Combined analysis showed that there was no significant difference in MTHFR 677C/T genotype distribution between psoriasis and control subjects in the comparisons C vs T, CC vs CT + TT, CC + CT vs TT, CC vs TT, and CC vs CT [respectively: odds ratio (OR) = 0.98, 95% confidence interval (CI) = 0.76-1.26, P = 0.882; OR = 1.11, 95%CI = 0.81-1.51, P = 0.526; OR = 0.79, 95%CI = 0.53-1.19, P = 0.261; OR = 0.88, 95%CI = 0.51-1.52, P = 0.648; OR = 1.19, 95%CI = 0.90-1.58, P = 0.217]. Subgroup analysis by ethnicity also showed no significant association between MTHFR 677C/T polymorphism and psoriasis risk in both Asian and Caucasian populations. In conclusion, this meta-analysis indicates that MTHFR 677C/T polymorphism may not be associated with psoriasis risk.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Single Nucleotide Polymorphisms-SNPs
Pharmacogenomics: Identification of New Drug Targets
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...

